A 42-year-old woman with cystic fibrosis is admitted with acute exacerbation of Pseudomonas aeruginosa respiratory infection. She is prescribed tobramycin 7 mg/kg intravenously once daily. On day 3 of therapy, she develops sudden-onset vertigo, nausea, and nystagmus. Audiometry shows bilateral sensorineural hearing loss in the high-frequency range (4–8 kHz). Her serum creatinine remains normal at 0.9 mg/dL. Which of the following best explains the ototoxicity observed in this patient?

Explanation

## Aminoglycoside Ototoxicity: Cochlear Mechanism **Key Point:** Aminoglycoside ototoxicity is irreversible, dose-dependent, and primarily targets outer hair cells of the cochlea via oxidative stress and mitochondrial dysfunction. ### Pathophysiology of Cochlear Damage Aminoglycosides accumulate in the inner ear via: 1. **Endolymphatic uptake** through the round window membrane 2. **Preferential accumulation in outer hair cells** (OHCs) of the organ of Corti 3. **Mitochondrial damage** in the stria vascularis (the energy-producing epithelium of the cochlea) 4. **ROS generation** via interaction with iron (Fenton reaction), causing lipid peroxidation and DNA damage 5. **Apoptosis and necrosis** of OHCs, leading to irreversible sensorineural hearing loss **High-Yield:** Aminoglycoside ototoxicity is **irreversible** and **cumulative**. Once OHCs are destroyed, they cannot regenerate in mammals. The high-frequency hearing loss (4–8 kHz) occurs first and is characteristic. ### Clinical Features of Aminoglycoside Ototoxicity | Feature | Cochlear Toxicity | Vestibular Toxicity | |---------|-------------------|---------------------| | **Onset** | Insidious (days to weeks) | Acute (hours to days) | | **Symptoms** | Tinnitus, high-frequency hearing loss | Vertigo, nausea, nystagmus, ataxia | | **Audiometry** | Sensorineural loss at 4–8 kHz first | N/A (clinical diagnosis) | | **Reversibility** | **Irreversible** | May partially recover | | **Risk factors** | Age >50, renal impairment, loop diuretics | Same as cochlear | **Clinical Pearl:** This patient has **both** cochlear and vestibular toxicity—the audiometry confirms cochlear damage (high-frequency SNHL), and the acute vertigo/nystagmus indicates vestibular involvement. Vestibular toxicity may partially recover, but cochlear damage is permanent. ### Why This Patient Is at Risk - **Cystic fibrosis**: Chronic lung disease with recurrent infections → repeated aminoglycoside exposure - **Cumulative dosing**: Even once-daily dosing accumulates over multiple courses - **Concomitant risk factors**: Loop diuretics (if used for pulmonary edema) synergize ototoxicity - **Age 42**: Moderate age-related hearing loss may be present **Mnemonic for aminoglycoside ototoxicity: "OTO-TOXIC"** - **O**uter hair cells destroyed (irreversible) - **T**oxicity is dose-dependent and cumulative - **O**xidative stress (ROS via Fenton reaction) - **T**iming: high-frequency loss first (4–8 kHz) - **O**xidative phosphorylation impaired (mitochondrial dysfunction) - **X**enobiotic accumulation in endolymph - **I**rreversible (unlike vestibular toxicity) - **C**ochlear > vestibular (though both can occur) ### Mechanism Diagram ```mermaid flowchart TD A[Aminoglycoside enters inner ear via round window]:::action --> B[Accumulates in outer hair cells]:::action B --> C[Binds to mitochondrial ribosomes]:::action C --> D[Inhibits oxidative phosphorylation]:::action D --> E[ROS generation via Fenton reaction]:::action E --> F[Lipid peroxidation and DNA damage]:::action F --> G[Apoptosis of OHCs]:::urgent G --> H[Irreversible sensorineural hearing loss]:::outcome H --> I[High-frequency loss 4-8 kHz first]:::outcome ``` **Warning:** Do not confuse aminoglycoside ototoxicity with conductive hearing loss (ossicular damage) or temporary endolymphatic hydrops. Aminoglycoside damage is **permanent** because outer hair cells do not regenerate in humans.